{"id": "236951", "url": "https://fevir.net/resources/Composition/236951", "date": "2025-10-07T17:12:54.639Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"], "versionId": "107", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "type": {"text": "Summary of Findings", "coding": [{"code": "SummaryOfFindings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "SummaryOfFindings"}]}, "title": "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "author": [{"display": "Qiukui Hao"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}}}, {"type": "part-of", "targetReference": {"type": "Composition", "display": "ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}}}, {"type": "cite-as", "targetMarkdown": "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "236951", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"coding": [{"code": "column-headers", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Column Headers"}]}, "title": "Column Headers", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Outcome</p></div>", "status": "generated"}, "title": "Outcome Measure"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Sample Size</p></div>", "status": "generated"}, "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result Without Treatment</p></div>", "status": "generated"}, "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Observed)</p></div>", "status": "generated"}, "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Calculated)</p></div>", "status": "generated"}, "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Effect Estimate</p></div>", "status": "generated"}, "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Certainty of Evidence</p></div>", "status": "generated"}, "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What this means</p></div>", "status": "generated"}, "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of Findings"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Summary of Findings", "section": [{"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: All-cause mortality", "reference": "EvidenceVariable/236953", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313956", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "All-cause mortality", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>All-cause mortality</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: All-cause mortality", "reference": "EvidenceVariable/236953", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313956", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.24</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236955", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.22</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293980", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>21.8%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236955", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -2.3% ( -4% to -0.4%); Odds Ratio 0.88 ( 0.79 to 0.98)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Cardiovascular mortality", "reference": "EvidenceVariable/236956", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313957", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Cardiovascular mortality", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Cardiovascular mortality</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Cardiovascular mortality", "reference": "EvidenceVariable/236956", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313957", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.16</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236958", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.15</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>15.2%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236958", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.5% ( -2.2% to 1.2%); Odds Ratio 0.96 ( 0.84 to 1.09)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal myocardial infarction", "reference": "EvidenceVariable/236959", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313958", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Nonfatal myocardial infarction", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal myocardial infarction</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal myocardial infarction", "reference": "EvidenceVariable/236959", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313958", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236960", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.18</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236961", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.17</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293982", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236961", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236960", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.7% ( -2.4% to 1.1%); Odds Ratio 0.95 ( 0.84 to 1.08)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236960", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236960", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236960", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal stroke", "reference": "EvidenceVariable/236962", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313959", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Nonfatal stroke", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal stroke</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal stroke", "reference": "EvidenceVariable/236962", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313959", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236963", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.17</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236964", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.19</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293983", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>19.2%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236964", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236963", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 2.7% ( 0.4% to 5.3%); Odds Ratio 1.2 ( 1.03 to 1.41)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236963", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236963", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p> SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236963", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: End-stage kidney disease", "reference": "EvidenceVariable/236965", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313960", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "End-stage kidney disease", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>End-stage kidney disease</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: End-stage kidney disease", "reference": "EvidenceVariable/236965", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313960", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236966", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.12</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236967", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.11</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.9%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236967", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236966", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -1% ( -3.4% to 2%); Odds Ratio 0.91 ( 0.69 to 1.2)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236966", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236966", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236966", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Heart failure", "reference": "EvidenceVariable/236968", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313961", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Heart failure", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Heart failure</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Heart failure", "reference": "EvidenceVariable/236968", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313961", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data found.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236969", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.22</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236970", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.18</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293985", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17.6%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236970", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236969", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -4.8% ( -6.6% to -2.7%); Odds Ratio 0.74 ( 0.65 to 0.85)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236969", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236969", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236969", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Diabetic ketoacidosis", "reference": "EvidenceVariable/236971", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313962", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Diabetic ketoacidosis", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Diabetic ketoacidosis</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Diabetic ketoacidosis", "reference": "EvidenceVariable/236971", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313962", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236972", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236973", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293986", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.2%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236973", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236972", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.1% ( 0% to 0.3%); Odds Ratio 1.71 ( 0.79 to 3.69)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236972", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236972", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236972", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Serious hyperglycaemia", "reference": "EvidenceVariable/236974", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313963", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Serious hyperglycaemia", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Serious hyperglycaemia</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Serious hyperglycaemia", "reference": "EvidenceVariable/236974", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313963", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236975", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.01</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236976", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.01</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1.5%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236976", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236975", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.5% ( -0.2% to 1.9%); Odds Ratio 1.48 ( 0.75 to 2.93)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236975", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236975", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236975", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Genital infection", "reference": "EvidenceVariable/236977", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313964", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Genital infection", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Genital infection</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Genital infection", "reference": "EvidenceVariable/236977", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313964", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236978", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.05</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236979", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.21</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293988", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>20.8%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236979", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236978", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 15.8% ( 6.4% to 29.9%); Odds Ratio 5 ( 2.45 to 10.2)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236978", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236978", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236978", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Severe gastrointestinal events", "reference": "EvidenceVariable/236980", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313965", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Severe gastrointestinal events", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Severe gastrointestinal events</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Severe gastrointestinal events", "reference": "EvidenceVariable/236980", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313965", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>7 studies, 24638 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.04</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236982", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.1</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293989", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.2%</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236982", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 5.8% ( 0.9% to 14.2%); Odds Ratio 2.46 ( 1.22 to 4.97)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Very low certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236981", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Health-related quality of life", "reference": "EvidenceVariable/236983", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109587", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Health-related quality of life", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Health-related quality of life</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Health-related quality of life", "reference": "EvidenceVariable/236983", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109587", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data found.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236985", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293990", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236985", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Standardized Mean Difference 0.01 ( -0.19 to 0.2)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Low certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236984", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}, {"code": {"coding": [{"code": "summary-of-findings-entry-for-a-single-outcome", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary of findings entry for a single outcome"}]}, "focus": {"type": "EvidenceVariable", "display": "OutcomeDefinition: Body weight", "reference": "EvidenceVariable/236986", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109588", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Body weight", "section": [{"code": {"coding": [{"code": "outcome-measure", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Outcome Measure"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Body weight</p></div>", "status": "generated"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: Body weight", "reference": "EvidenceVariable/236986", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109588", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Outcome"}, {"code": {"coding": [{"code": "sample-size", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Sample Size"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1139 participants</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Sample Size"}, {"code": {"coding": [{"code": "result-with-comparator-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with comparator alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236988", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result Without Treatment"}, {"code": {"coding": [{"code": "result-with-intervention-alone", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "empty"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Evidence/293991", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-intervention-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Observed"}, {"code": {"text": "result with intervention with calculated value derived from the control group and effect estimate", "coding": [{"code": "result-with-intervention-alone-calculated", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention alone (calculated)"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Evidence/236988", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Result With Treatment--Derived"}, {"code": {"coding": [{"code": "result-with-intervention-vs-comparator", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Result with intervention vs. comparator"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Mean Difference -0.47 Kg ( -0.09 Kg to -0.85 Kg)</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Effect Estimate"}, {"code": {"coding": [{"code": "certainty-of-evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Certainty of Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Certainty of Evidence"}, {"code": {"coding": [{"code": "assertion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Assertion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</p></div>", "status": "generated"}, "entry": [{"type": "Evidence", "display": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "reference": "Evidence/236987", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Assertion"}]}], "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "groups", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Groups"}]}, "title": "Groups", "section": [{"code": {"coding": [{"code": "population", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Population"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Total Group", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "intervention-group", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Intervention Group"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Intervention Group", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "comparator-group", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Comparator Group"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Comparator Group", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "GroupAssignment", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "GroupAssignment"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Group Assignment", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}, {"code": {"coding": [{"code": "variables", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Variables"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "entry": [{"type": "EvidenceVariable", "display": "OutcomeDefinition: All-cause mortality", "reference": "EvidenceVariable/236953", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313956", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Cardiovascular mortality", "reference": "EvidenceVariable/236956", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313957", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal myocardial infarction", "reference": "EvidenceVariable/236959", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313958", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Nonfatal stroke", "reference": "EvidenceVariable/236962", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313959", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: End-stage kidney disease", "reference": "EvidenceVariable/236965", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313960", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Heart failure", "reference": "EvidenceVariable/236968", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313961", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Diabetic ketoacidosis", "reference": "EvidenceVariable/236971", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313962", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Serious hyperglycaemia", "reference": "EvidenceVariable/236974", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313963", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Genital infection", "reference": "EvidenceVariable/236977", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313964", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Severe gastrointestinal events", "reference": "EvidenceVariable/236980", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313965", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Health-related quality of life", "reference": "EvidenceVariable/236983", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109587", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "EvidenceVariable", "display": "OutcomeDefinition: Body weight", "reference": "EvidenceVariable/236986", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-109588", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "title": "Variables (Measures)"}]}